Skip to main content

MoneyWorks4Me

Nectar Lifesciences board approves unaudited financial results

14 Nov 2019 Evaluate

Nectar Lifesciences has informed that the Board of Directors of the Company at their meeting held today duly approved and took on record the Unaudited Standalone & Consolidated Financial results for the quarter and half year ended on September 30, 2019, which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1768.00
Dr. Reddys Labs. 1340.25
Cipla 1382.00
Lupin 1996.55
Zydus Lifesciences 1239.95
View more..